Inhibition of Cyclooxygenase-1 or -2 on Insulin Sensitivity in Healthy Subjects

The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2 inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind, controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers. Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib. After randomization, all subjects received an oral morning dose of ASA 100 mg (n = 7), celecoxib 200 mg (n = 7), or placebo for the control group (n = 7) during a period of 15 days. Before and after of the study period, a metabolic profile was measured in all participants. An insulin tolerance test (ITT) was performed to assess insulin sensitivity, and the constant for the serum glucose disappearance rate (K ITT) was calculated. Clinical and metabolic characteristics were similar between groups. The K ITT calculated with the ITT was higher after celecoxib than at baseline (4.8 ± 0.9 vs. 4.3 ± 0.6 %/min, p = 0.04), indicating improvement in insulin sensitivity. Neither ASA nor placebo administrations modified insulin sensitivity. In conclusion, COX-2-selective inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy subjects.

Key words:

Cyclooxygenase-1 - Cyclooxygenase-2 - Insulin Sensitivity - Insulin Action - COX - Insulin Tolerance Test

References

• 1 Jouzeau J -Y, Terlain B, Abid A, Nédélec E, Netter P. Cyclooxygenase isoenzymes.  Drug. 1977;  53 563-582
• 2 Lipsky P E, Abramson S B, Crofford L, Dubois R N, Simon L S, Van de Putte L BA. The classification of cyclooxygenase inhibitors.  J Rheumatol. 1998;  25 2298-2303
• 3 Newsholme E A. Some experiments on factors that can change insulin sensitivity.  Ann Med. 1990;  22 181-184
• 4 Leighton B, Chaliss R AJ, Newsholme E A. The role of prostaglandins as modulators of insulin-stimulated glucose metabolism in skeletal muscle.  Horm Metab Res. 1990;  22 (Suppl.) 89-95
• 5 Wasner H K, Weber S, Partke H J, Amini-Hadi-Kiashar H. Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action.  Acta Diabetol. 1994;  31 175-182
• 6 Paolisso G, Gambardella A, Saccomanno F, Varricchio G, D'Amore A, Varricchio M. Low-dose iloprost infusion improves insulin action and non-oxidative glucose metabolism in hypertensive patients.  Eur J Clin Pharmacol. 1995;  48 333-338
• 7 González-Ortiz M, Martínez-Abundis E, Escalante-Pulido J M. Comparison of homeostasis model analysis with insulin tolerance test in the assessment of insulin resistance in healthy young people.  Diab Nutr Metab. 1998;  11 136-139
• 8 Summers S A, Yin V P, Whiteman E L, Garza L A, Cho H, Tuttle R L, Birnbaum M J. Signaling pathways mediating insulin-stimulated glucose transport.  Ann N Y Acad Sci. 1999;  892 69-186
• 9 Robertson P. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis.  Diabetes. 1998;  47 379-1383
• 10 Meade E A, Smith W L, DeWitt D L. Diferential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.  J Biol Chem. 1993;  268 6610-6614
• 11 Green A, Walters D J, Belt S E. Insulin resistance in adipocytes after downregulation of Gi subtypes.  Am J Physiol. 1997;  273 E254-E261
• 12 Virkamäki A, Yki-Järvinen H. Role of prostaglandins in mediating alterations in glucose metabolism during acute endotoxemia in the rat.  Endocrinology. 1995;  136 701-1706
• 13 Salazar-Páramo M, González-Ortiz M, González-López L, Sánchez-Ortiz A, Valera-González I C, Martínez-Abundis E, Balcázar-Muñoz B R, García-González A, Gámez-Nava J I. Serum leptin levels in patients with rheumatoid arthritis.  J Clin Rheumatol. 2001;  7 57-60
• 14 González-Ortiz M, Martínez-Abundis E, Pascoe-González S. Comparison between usual and low doses of insulin in the assessment of insulin sensitivity with a short insulin tolerance test in obese women.  Arch Med Res. 1999;  30 385-387
• 15 Suzuki M, Ikebuchi M, Shinozaki K, Hara Y, Tsushima M, Matsuyama T, Harano Y. Mechanism and clinical implication of insulin resistance syndrome.  Diabetes. 1996;  45 (Suppl. 3) S52-S54